Sonrai, a leader in AI precision medicine, has reached an exciting milestone with the completion of its latest investment round. The round was led by UK-based private equity firm Beach Equity Investments (BEI), alongside further support from existing investors.
The investment coincides with the appointment of Chris Brooks, former Johnson & Johnson business leader, as Chief Commercial Officer. Chris will lead Sonrai’s commercial expansion, bringing deep global experience to support the company’s mission of delivering advanced AI and data solutions to the pharma and biotech sectors.
With its proprietary AI precision medicine platform, Sonrai is already helping innovators accelerate the discovery and development of new therapies. The combination of fresh investment and expanded leadership provides the company with a strong foundation to scale its commercial reach, deepen industry partnerships, and enhance the value it delivers to customers.
As a QUBIS portfolio company and Queen’s University Belfast spin-out, Sonrai’s growth highlights the strength of innovation emerging from Northern Ireland and its potential to make a global impact in healthtech.
This latest milestone marks the next stage in Sonrai’s journey as it continues to establish itself as a leading supplier of AI-driven insights for precision medicine.
Learn more about Sonrai HERE